Investor confidence is high in Merit Medical (MMSI) stock, thanks to solid prospects.

Large allocations to the purchase of fixed assets may anticipate growth Continue reading...

Investor confidence is high in Surmodics (SRDX) stock, thanks to solid prospects.

IBD Live Q&A Question Answer(s) Early question. How often is the BOUT ETF portfolio updated? Every week. Ah, another morning and Mozart is joining us at IBDLive. What an honor! I'm wanting to get some Led Zep...just too much$$ What are your thoughts on GDDY? Building a nice base. V-shaped, but it's on breakout watch for sure. Big annual earnings...

The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.

(Bloomberg) -- Dexcom Inc.’s recent entry into the S&P 500 gave the benchmark a new leader for the year, dethroning stocks like Newmont Corp. and Regeneron Pharmaceuticals Inc. that have seen share prices surge in the face of the coronavirus pandemic.The medical device company’s 85% rally this year is 30 percentage points ahead of the next four closest stocks in the S&P 500. While Dexcom rose to a fresh record last week after replacing Allergan Plc in the index, the debate for further gains is a hot one.Dexcom is among the few medtech companies that benefits from Covid-19. Its biggest Wall Street bull, Baird analyst Jeff Johnson, expects the stock to increase another 18% over the next 12 months. Other analysts including the team from Wells Fargo have cautioned that the current valuation matches its position in the fast-growing diabetes management market.Dexcom’s continuous glucose monitoring system, or CGM, allows diabetic patients to monitor their blood sugar levels day and night in place of fingersticks. The company’s G6 system is a small, wearable sensor and transmitter that sends a patient’s glucose number to their smartphone or watch every five minutes. The easy-to-use technology has served as a boon for sales with the company reporting 44% revenue growth in the first three months of the year.“It is an expensive stock, but you’re starting to see some real evidence that there are incremental revenue opportunities that aren’t in models that could emerge over the next few years,” Johnson said by telephone. He sees potential for more sales in both Type 1 and Type 2 diabetes due to CGM’s “high accuracy, improved convenience.”While the Covid-19 pandemic sent shockwaves through much of the medical technology landscape as elective surgeries were halted, Dexcom has seen continued demand for its products. The fact that diabetics have greater odds of complications related to coronavirus has “driven home the need to get even more diabetes patients on CGM because of the higher risk,” according to Johnson.The stock’s record-setting run has left many analyst price targets in the dust. Tuesday’s $404.57 close was higher than all but two 12-month price targets among analysts surveyed by Bloomberg. The average price target actually implies shares will lose 10% of their value a year from now.Wells Fargo analyst Larry Biegelsen, who started covering Dexcom with an equal weight rating just last week, thinks the next-generation G7 system could drive market share gains next year. The upgraded CGM system paired with international demand and use by patients in hospitals could be significant drivers of growth, Biegelsen wrote. But the near-term opportunities are already reflected in the stock price, he said.Smaller diabetes stocks have also captivated health specialists over recent years as investors look to cash in on the booming market. Insulet Corp., a $13 billion maker of the wearable and tubeless insulin delivery system OmniPod, has surged more than 580% in the past five years. And Tandem Diabetes Care Inc.’s insulin pump business has fueled its market value surge to $5 billion from less than $20 million three years ago.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

For years there has been chatter about the "S&P; phenomenon," which supposedly confers a bump in price to new additions to the index.

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

Guru releases portfolio for the 1st quarter Continue reading...

This deal is expected to bolster Allscripts' (MDRX) Clinical and Financial Solutions segment.

Q1 2020 DexCom Inc Earnings Call

DexCom Prices Offering of Upsized $1.05 Billion of 0.25% Convertible Senior Notes

ESG stocks bear lesser financial risk due to their focus on environment, employees and supply chain. Investment in these companies can return well.

Brown Advisory recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Large-Cap Growth Fund posted a return of -13.05% for the quarter, outperforming its benchmark, the Russell 1000 Growth Index which returned -14.10% in the same quarter. You should check out Brown Advisory’s top 5 stock picks for […]

Health care, one of the largest and most complex sectors, is comprised of a broad range of companies that sell medical products and services. The health care sector includes companies that sell drugs, medical devices, and insurance, as well as hospitals and health care providers. Health care stocks, as represented by the Health Care Select Sector SPDR ETF (XLV), have outperformed the broader market, providing investors with a total return of 16.3% compared to the S&P 500's total return of 5.9% over the past 12 months. In 2020, health care stocks have recouped nearly all of their losses since their March plunge while the broader market continues to suffer from the global coronavirus pandemic. The market performance numbers and the statistics in the tables in this story are as of May 20.

Glucose monitoring company DexCom Inc. is in Jim Cramer's Covid-19 index, discussed here on Real Money. Prices have soared in just the past three months. In the daily bar chart of DXCM, below, we can see that prices look extended when compared to the rising 50-day moving average line and the rising 200-day moving average line.

This development, which is in response to the challenges brought on by the pandemic, is expected to boost Varian's (VAR) Oncology segment.

Invesco QQQ (QQQ), which tracks the Nasdaq 100 Index, joined the $100 billion club of AUM last week.

Amazon is often thought of as the perfect S&P; 500 stock — especially amid the coronavirus stock market. But it's possible to beat Jeff Bezos.

Is (DXCM) Outperforming Other Medical Stocks This Year?